News und Analysen

A new month is here. And with it comes a new opportunity to invest in spectacular dividend stocks.

Three Motley Fool contributors think they know some great candidates to buy in July. Here's why

Drug companies Merck (NYSE: MRK) and AbbVie (NYSE: ABBV) have been two of the best pharmaceutical investments, easily delivering better total returns than the S&P 500 average over the past three

Temperatures are rising. And so are concerns about what's next for the stock market. The answer to the former issue is air conditioning and/or a cool swim. The latter is more challenging.

However

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Vertex Pharmaceuticals (NASDAQ: VRTX) is heading toward a big moment: a regulatory decision on what may become its next game-changing product. And this potential product, exa-cel for blood

Epcoritamab, a cancer drug co-developed by AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB), was recently given the green light by the Food and Drug Administration to be used as a treatment for adults

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

Shares in Pfizer (NYSE: PFE) were falling recently after it discontinued clinical trials for a potential diabetes and weight-loss therapy. The drop was due to negative perceptions after lotiglipron

On June 26, FibroGen's (NASDAQ: FGEN) lead program, pamrevlumab, reported poor late-stage clinical trial results for the second time in a month, sending its stock barreling downward to the tune of

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

On June 26, Pfizer (NYSE: PFE) gave investors an update that they probably didn't like. One of its two candidates for treating diabetes and obesity, called lotiglipron, will not be developed any

MicroVision (NASDAQ: MVIS) closed the work week in style, with its stock price rising by over 17% on Friday. That was a far better performance than the S&P 500 index's 1.2% increase. Investors

Shares of biosimilar pharmaceutical maker Alvotech (NASDAQ: ALVO) were up more than 11% as of noon on Friday. On Thursday, it plunged more than 6% after the company announced it had received a

Shares of CymaBay Therapeutics (NASDAQ: CBAY) were up more than 37% as of 11:15 a.m. ET on Friday. The clinical-stage biotech saw its shares rise after Ipsen and Genfit announced phase 3 trials data

Things have not quite gone as hoped lately for shares of Sarepta Therapeutics (NASDAQ: SRPT). Recently, the biotech received approval from the Food and Drug Administration (FDA) for its cutting-edge

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Shares of Opko Health (NASDAQ: OPK) were up more than 11% around 2:30 p.m. ET on Thursday. The healthcare company announced after the markets closed on Wednesday that a treatment for pediatric

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of

Biotech heavyweight Amgen (NASDAQ: AMGN) will probably continue to be an active player in the merger and acquisition (M&A) scene, regardless of what happens with its proposed $28 billion buyout of